News

AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school ...
Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer saw a staggering increase in call options trading, with investors snapping up 539,824 contracts, marking a 286% jump ...
While you can't see Buffett's other seven high-yielding dividend stocks in Berkshire's filings, the company, in essence, has ...
These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.
Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...
Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...
Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...
Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...
While its shares have been lagging the market significantly, that could change in the next decade as financial results ...
Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.